Summit Therapeutics’ ivonescimab shows strong efficacy in trials, with Cantor Fitzgerald predicting a 50% market share in the $100B VEGF x PD-(L)1 space.
Latest Ratings for SMMT
DateFirmActionFromTo Nov 2020HC Wainwright & Co.DowngradesBuyNeutral Mar 2020HC Wainwright & Co.Initiates Coverage OnBuy Jun 2018Janney Montgomery ScottDowngradesBuyNeutral